Results 181 to 188 of about 35,072 (188)

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.

The Lancet, 2017
Roy M Fleischmann, E. Mysler, S. Hall, A. Kivitz, R. Moots, Zhen Luo, R. Demasi, K. Soma, Richard Y Zhang, L. Takiya, S. Tatulych, C. Mojcik, S. Krishnaswami, S. Menon, J. Smolen   +14 more
semanticscholar   +1 more source

Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis

Rheumatology, 2008
P Tynjälä, K Kotaniemi, KRISTIINA Aalto   +2 more
exaly  

The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis

American Journal of Clinical Dermatology, 2012
Craig Leonardi, Kim A Papp, Bruce Strober   +2 more
exaly  

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Lancet, The, 2013
Cem Gabay, Paul Emery, Rieke Alten
exaly  

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

British Journal of Dermatology, 2008
Kim A Papp, R G Langley, J -P Ortonne
exaly  

Adalimumab

Reactions Weekly, 2010
openaire   +1 more source

Adalimumab

Reactions Weekly, 2020
openaire   +1 more source

Adalimumab

Reactions Weekly, 2012
openaire   +1 more source